Roche buys into Blueprint's RET inhibitor

Saturday, July 18, 2020 - 20:40 in Mathematics & Economics

The deal positions pralsetinib to compete against Lilly's Retevmo

Read the whole article on C&EN

More from C&EN

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net